Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-metastatic breast cancer patients discontinuing aromatase inhibitor on denosumab: what next?

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations.

Journal of bone oncology·2021
Same author

Variabilities in µQCT-based FEA of a tumoral bone mice model.

Journal of biomechanics·2021
Same author

The Multiple Sclerosis Severity Score: fluctuations and prognostic ability in a longitudinal cohort of patients with MS.

Multiple sclerosis journal - experimental, translational and clinical·2019
Same author

[Pharmaceutical interviews for rheumatoid arthritis patients: Perceptions and expectations of community pharmacists].

Annales pharmaceutiques francaises·2018
Same author

Effect of intra-tibial injection on mechanical properties of mouse bone.

Computer methods in biomechanics and biomedical engineering·2017
Same journal

Association of epiretinal membranes with disability in people with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Epiretinal membranes in multiple sclerosis: A window into glial pathobiology?

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

UK consensus on pregnancy in multiple sclerosis: An update to 'Association of British Neurologists' guidance.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Comparative effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis on clinical relapses and radiological outcomes in British Columbia, Canada.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Invisible symptoms in multiple sclerosis and their impact on social role participation: A multidimensional analysis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Assessing disability progression with the Multiple Sclerosis Functional Composite.

R A Rudick1, C H Polman, J A Cohen

  • 1Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH 44106, USA. rudickr@ccf.org

Multiple Sclerosis (Houndmills, Basingstoke, England)
|August 12, 2009
PubMed
Summary
This summary is machine-generated.

New methods using Multiple Sclerosis Functional Composite (MSFC) component data define patient-specific disability progression. These MSFC progression measures are sensitive to change and demonstrate treatment effects in clinical trials.

More Related Videos

Computerized Adaptive Testing System of Functional Assessment of Stroke
05:21

Computerized Adaptive Testing System of Functional Assessment of Stroke

Published on: January 7, 2019

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Related Experiment Videos

Last Updated: Jun 21, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Computerized Adaptive Testing System of Functional Assessment of Stroke
05:21

Computerized Adaptive Testing System of Functional Assessment of Stroke

Published on: January 7, 2019

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Area of Science:

  • Neurology
  • Clinical Trial Analysis
  • Biostatistics

Background:

  • The Multiple Sclerosis Functional Composite (MSFC) traditionally uses a composite Z-score, making clinical interpretation of changes difficult.
  • This study introduces a novel approach using individual MSFC component data to define patient-specific disease progression events.

Purpose of the Study:

  • To evaluate a new method for analyzing disability progression in multiple sclerosis (MS) using MSFC component data.
  • To establish patient-specific disease progression events for more sensitive clinical trial analysis.

Main Methods:

  • Defined MSFC progression as a ≥15% or ≥20% worsening from baseline in at least one MSFC component, sustained for ≥3 months.
  • Analyzed data from natalizumab clinical studies (AFFIRM and SENTINEL) to determine progression rates.
  • Assessed correlations between MSFC progression and other clinical measures (EDSS, relapse rate, SF-36 PCS) and sensitivity to treatment effects.

Main Results:

  • Both MSFC Progression-15 and MSFC Progression-20 identified substantial patient progression.
  • MSFC Progression-15 was more sensitive than MSFC Progression-20 at 1 and 2 years.
  • MSFC progression measures significantly correlated with Expanded Disability Status Scale (EDSS) changes, relapse rates, and SF-36 Physical Component Summary (PCS) scores.
  • One-year MSFC progression predicted two-year EDSS progression.
  • Both MSFC progression endpoints demonstrated significant treatment effects in both AFFIRM and SENTINEL studies.

Conclusions:

  • MSFC Progression-15 and MSFC Progression-20 are sensitive and reliable measures of disability progression in MS.
  • These novel MSFC progression metrics correlate well with established clinical outcomes (EDSS, relapse rates, SF-36 PCS).
  • The MSFC progression measures are capable of detecting therapeutic effects in randomized controlled trials.